Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eye & ENT Hospital of Fudan University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
University of Cincinnati
Maria Sklodowska-Curie National Research Institute of Oncology
Heidelberg University
Radboud University Medical Center
Qingdao Central Hospital
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Fudan University
Radboud University Medical Center
University of Iowa
University of Virginia
Shanghai Proton and Heavy Ion Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Pittsburgh
Seoul National University Hospital
Seoul National University Hospital
Gustave Roussy, Cancer Campus, Grand Paris